Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
V Goede, K Fischer, R Busch, A Engelke… - … England Journal of …, 2014 - Mass Medical Soc
Background The monoclonal anti-CD20 antibody rituximab, combined with
chemotherapeutic agents, has been shown to prolong overall survival in physically fit …
chemotherapeutic agents, has been shown to prolong overall survival in physically fit …
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
K Bauer, M Rancea, V Roloff, T Elter… - Cochrane Database …, 2012 - cochranelibrary.com
Background Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and
is the most common lymphoid malignancy in western countries. Standard treatments include …
is the most common lymphoid malignancy in western countries. Standard treatments include …
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
G Cartron, S de Guibert, MS Dilhuydy… - Blood, The Journal …, 2014 - ashpublications.org
GAUGUIN evaluated the safety and efficacy of obinutuzumab (GA101) monotherapy in
patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In phase 1 (dose …
patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In phase 1 (dose …
Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients
R Foà, I Del Giudice, A Cuneo… - American journal of …, 2014 - Wiley Online Library
In a phase II trial, we evaluated chlorambucil and rituximab (CLB‐R) as first‐line induction
treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) …
treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) …
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
P Jain, S O'Brien - Expert opinion on biological therapy, 2013 - Taylor & Francis
Introduction: The last decade has witnesd immense progress in the treatment of chronic
lymphocytic leukemia (CLL). Chemoimmunotherapy (CIT) combining rituximab and …
lymphocytic leukemia (CLL). Chemoimmunotherapy (CIT) combining rituximab and …
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
V Goede, K Fischer, R Busch, U Jaeger, MS Dilhuydy… - Leukemia, 2013 - nature.com
Intensive chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab is the
standard first line treatment in younger and physically fit patients with chronic lymphocytic …
standard first line treatment in younger and physically fit patients with chronic lymphocytic …
Non-Hodgkin's lymphomas, version 3.2012
AD Zelenetz, WG Wierda, JS Abramson… - Journal of the National …, 2012 - jnccn.org
These NCCN Guidelines Insights summarize several key updates to the 2012 NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas …
Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas …
[PDF][PDF] Individualizing treatment decisions for older adults with hematologic malignancies
HD Klepin, D Rizzieri, A Palumbo… - American Society of …, 2013 - ascopubs.org
Hematologic malignancies are a common cause of morbidity and mortality among older
adults, who represent the majority of patients diagnosed with these diseases. Treatment …
adults, who represent the majority of patients diagnosed with these diseases. Treatment …
Treatment of chronic lymphocytic leukemia
A Janssens - Transfusion and Apheresis Science, 2013 - trasci.com
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in Western
countries with an incidence of 3.8 per 100,000 person-years [1]. CLL occurs twice as often in …
countries with an incidence of 3.8 per 100,000 person-years [1]. CLL occurs twice as often in …
Chronische lymphatische Leukämie
CM Wendtner - DMW-Deutsche Medizinische Wochenschrift, 2012 - thieme-connect.com
Die chronische lymphatische Leukämie (CLL) als häufigste Leukämie im Erwachsenenalter–
mit einer Inzidenz von bis zu 30 pro 100000 pro Jahr bei den über 70-Jährigen–ist in den …
mit einer Inzidenz von bis zu 30 pro 100000 pro Jahr bei den über 70-Jährigen–ist in den …